| P2093 | author name string | R Flick | |
| | R B Mandell | |
| | R Koukuntla | |
| P2860 | cites work | Suspension-Vero cell cultures as a platform for viral vaccine production | Q42811666 |
| | Virus-like particles: innate immune stimulators | Q45367230 |
| | Interventions Against West Nile Virus, Rift Valley Fever Virus, and Crimean-Congo Hemorrhagic Fever Virus: Where Are We? | Q45372924 |
| | Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza | Q21091074 |
| | A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection | Q24631774 |
| | Complete Genome Analysis of 33 Ecologically and Biologically Diverse Rift Valley Fever Virus Strains Reveals Widespread Virus Movement and Low Genetic Diversity due to Recent Common Ancestry | Q27478367 |
| | Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. | Q30366836 |
| | Induction of long-term protective immune responses by influenza H5N1 virus-like particles. | Q30375255 |
| | Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus | Q30389157 |
| | Superior neutralizing antibody response and protection in mice vaccinated with heterologous DNA prime and virus like particle boost against HPAI H5N1 virus | Q30399477 |
| | A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets | Q30399675 |
| | Heterosubtypic antibody response elicited with seasonal influenza vaccine correlates partial protection against highly pathogenic H5N1 virus | Q30401524 |
| | Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge | Q33386427 |
| | Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines | Q33570326 |
| | Large-scale transient expression in mammalian cells for recombinant protein production | Q33597330 |
| | Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus | Q33617793 |
| | A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge | Q33621078 |
| | Vaccine potential of Nipah virus-like particles | Q33873756 |
| | Structures of virus and virus-like particles | Q33885190 |
| | Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention | Q33960690 |
| | Rift valley fever: recent insights into pathogenesis and prevention | Q34174444 |
| | Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever | Q34322342 |
| | Requirements for budding of paramyxovirus simian virus 5 virus-like particles. | Q34336746 |
| | Protection of Sheep against Rift Valley Fever Virus and Sheep Poxvirus with a Recombinant Capripoxvirus Vaccine | Q34431934 |
| | Efficient cellular release of Rift Valley fever virus requires genomic RNA. | Q34704620 |
| | Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies | Q40283103 |
| | Mucosal immunization of rhesus macaques with Rift Valley Fever MP-12 vaccine | Q40317212 |
| | Protection of MP-12-vaccinated rhesus macaques against parenteral and aerosol challenge with virulent rift valley fever virus | Q40321756 |
| | Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves | Q40322035 |
| | Parenteral vaccination of mammalian livestock with Newcastle disease virus-based vector vaccines offers optimal efficacy and safety | Q40322793 |
| | A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR(-/-) mice upon lethal virus challenge. | Q40325815 |
| | Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep | Q40358602 |
| | Hantavirus-like particles generated in CHO cells induce specific immune responses in C57BL/6 mice | Q40359887 |
| | Rift Valley fever virus: an unrecognized emerging threat? | Q40360325 |
| | Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus | Q40368584 |
| | A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity | Q40379142 |
| | An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus | Q40398800 |
| | Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus | Q40399200 |
| | Rift Valley fever virus lacking NSm proteins retains high virulence in vivo and may provide a model of human delayed onset neurologic disease. | Q40453546 |
| | Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus | Q40498246 |
| | Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles | Q40531044 |
| | Gp120 stability on HIV-1 virions and Gag-Env pseudovirions is enhanced by an uncleaved Gag core. | Q40626990 |
| | Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. | Q40632227 |
| | Mapping of the mutations present in the genome of the Rift Valley fever virus attenuated MP12 strain and their putative role in attenuation | Q40642621 |
| | Nucleotide sequence and coding strategy of the Uukuniemi virus L RNA segment | Q40731591 |
| | Efficacy of a Rift Valley fever virus vaccine against an aerosol infection in rats | Q40743768 |
| | Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep | Q40753243 |
| | Characterization of baculovirus-expressed Rift Valley fever virus glycoproteins synthesized in insect cells | Q40757347 |
| | Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins | Q40775631 |
| | Identification of mutations in the M RNA of a candidate vaccine strain of Rift Valley fever virus | Q40776401 |
| | Viral determinants of virulence for Rift Valley fever (RVF) in rats | Q40782624 |
| | Experimental Rift Valley fever in rhesus macaques | Q40789442 |
| | Pathogenesis of Rift Valley fever virus (RVFV) in inbred rats | Q40798305 |
| | Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator | Q40806370 |
| | Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development | Q40814834 |
| | Rift Valley fever virus vaccine trial: study of neutralizing antibody response in humans | Q40817416 |
| | A Rift Valley fever vaccine trial: 2. Serological response to booster doses with a comparison of intradermal versus subcutaneous injection | Q40817422 |
| | A rift Valley fever vaccine trial. I. Side effects and serologic response over a six-month follow-up | Q40841428 |
| | H9N2 avian influenza virus-like particle vaccine provides protective immunity and a strategy for the differentiation of infected from vaccinated animals | Q41378949 |
| | Virus-like particle production at low multiplicities of infection with the baculovirus insect cell system. | Q42046667 |
| | Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells | Q42073571 |
| | Rift Valley fever virus | Q34971963 |
| | Advances in Rift Valley fever research: insights for disease prevention | Q35077969 |
| | Importance of Vp1 calcium-binding residues in assembly, cell entry, and nuclear entry of simian virus 40. | Q35149110 |
| | Virus-like particles as immunogens | Q35295832 |
| | Human papillomavirus (HPV) 6, 11, 16, and 18 seroprevalence is associated with sexual practice and age: results from the multinational HPV Infection in Men Study (HIM Study) | Q35596329 |
| | Quantitative analysis of Nipah virus proteins released as virus-like particles reveals central role for the matrix protein | Q35608833 |
| | Exotic emerging viral diseases: progress and challenges | Q35971398 |
| | From gene to protein: a review of new and enabling technologies for multi-parallel protein expression | Q36049275 |
| | Filovirus-like particles as vaccines and discovery tools | Q36198685 |
| | Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals | Q36484009 |
| | Bioreactor systems for the production of biopharmaceuticals from animal cells | Q36501611 |
| | Virus-like particles: passport to immune recognition | Q36602264 |
| | Rift Valley fever virus structural proteins: expression, characterization and assembly of recombinant proteins. | Q36797004 |
| | A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil). | Q36822935 |
| | Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs | Q37087027 |
| | The RING domain and the L79 residue of Z protein are involved in both the rescue of nucleocapsids and the incorporation of glycoproteins into infectious chimeric arenavirus-like particles | Q37247924 |
| | Rift valley fever vaccines | Q37393780 |
| | Currently approved prophylactic HPV vaccines | Q37640113 |
| | Virus-like particles in vaccine development. | Q37798008 |
| | Two decades of plant-based candidate vaccines: a review of the chimeric protein approaches | Q37867011 |
| | Virus-like particles for antigen delivery at mucosal surfaces | Q37899815 |
| | Arbovirus vaccines; opportunities for the baculovirus-insect cell expression system | Q37904374 |
| | Large-scale production and purification of VLP-based vaccines | Q37904378 |
| | Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine | Q38915999 |
| | The Rift Valley fever epizootic in Egypt 1977–1978 1. Description of the epizootic and virological studies | Q39240187 |
| | Generation and analysis of infectious virus-like particles of uukuniemi virus (bunyaviridae): a useful system for studying bunyaviral packaging and budding | Q39292370 |
| | Virus-like particles expressing the nucleocapsid gene as an efficient vaccine against Rift Valley fever virus | Q39653963 |
| | Novel suspension cell-based vaccine production systems for Rift Valley fever virus-like particles | Q39676525 |
| | Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge | Q39754768 |
| | Immunogenicity and safety of an inactivated Rift Valley fever vaccine in a 19-year study. | Q39778317 |
| | Comparative analysis of the alphavirus-based vectors expressing Rift Valley fever virus glycoproteins | Q39779815 |
| | Optimization of chimeric HIV-1 virus-like particle production in a baculovirus-insect cell expression system | Q39830189 |
| | Respiratory syncytial virus subunit vaccine based on a recombinant fusion protein expressed transiently in mammalian cells | Q39832484 |
| | Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector | Q39877530 |
| | Efficient production of Rift Valley fever virus-like particles: The antiviral protein MxA can inhibit primary transcription of bunyaviruses | Q39893246 |
| | Priming with DNA plasmids encoding the nucleocapsid protein and glycoprotein precursors from Rift Valley fever virus accelerates the immune responses induced by an attenuated vaccine in sheep. | Q39953693 |
| | Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents | Q40042093 |
| P921 | main subject | Rift Valley fever | Q326638 |
| | Rift Valley fever virus | Q14276794 |
| | Rift Valley fever phlebovirus | Q24809101 |
| P1104 | number of pages | 9 | |
| P304 | page(s) | 142-150 | |
| P577 | publication date | 2012-09-01 | |
| P1433 | published in | Zoonoses and Public Health | Q15753252 |
| P1476 | title | Virus-like particle-based countermeasures against Rift Valley fever virus | |
| P478 | volume | 59 Suppl 2 | |